Stock Market News
Akers Biosciences buddies up with established US medical distributors
Healthcare developer and supplier Akers Biosciences has appointed two independent sales representatives (ISR) to assist with the US marketing and sales of its Heparin/PF4 Rapid Assay.
The agreements are with Opto-Systems, which has four decades of experience in medical device sales and distribution, and Herzog Surgical, a Sacramento-based company with a 30 year track record of specialised distribution of a wide range of medicinal products.
John Gormally, chief executive of Akers Biosciences, said of the appointments: "It represents the third wave of our commercialization strategy which included value captured in price, a strategy to target integrated delivery networks and now, a strategy to influence the clinical pathway by educating the clinical end-users on the critical medical benefits of adopting this rapid test for heparin platelet factor 4 antibodies."
The Heparin/PF4 Rapid Assay is a rapid test for heparin-induced thrombocytopenia (HIT), or low platelet count, which predisposes subjects to the formation of clots in blood vessels.
"We are thrilled to be working with Opto-Systems and Herzog Surgical whose respective specialized capabilities will bolster our sales efforts and allow our test to gain substantial additional regional coverage at a clinical level," said Gormally.
As of 1603 BST, Akers Biosciences' shares were up 5.78% at 43.90p.
The agreements are with Opto-Systems, which has four decades of experience in medical device sales and distribution, and Herzog Surgical, a Sacramento-based company with a 30 year track record of specialised distribution of a wide range of medicinal products.
John Gormally, chief executive of Akers Biosciences, said of the appointments: "It represents the third wave of our commercialization strategy which included value captured in price, a strategy to target integrated delivery networks and now, a strategy to influence the clinical pathway by educating the clinical end-users on the critical medical benefits of adopting this rapid test for heparin platelet factor 4 antibodies."
The Heparin/PF4 Rapid Assay is a rapid test for heparin-induced thrombocytopenia (HIT), or low platelet count, which predisposes subjects to the formation of clots in blood vessels.
"We are thrilled to be working with Opto-Systems and Herzog Surgical whose respective specialized capabilities will bolster our sales efforts and allow our test to gain substantial additional regional coverage at a clinical level," said Gormally.
As of 1603 BST, Akers Biosciences' shares were up 5.78% at 43.90p.
Related share prices |
---|
Akers Biosciences, Inc. (AKR) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price